Loading
A phase 2 trial of Mecapegfilgrastim and Dalpiciclib in Breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, active and no longer recruiting.
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer is a phase 2 interventional study registered as NCT05463601 by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, with 132 participants planned, started 2022-08-01 and due to reach its primary completion in 2025-01-31. Interventions recorded: Mecapegfilgrastim, dalpiciclib, exemestane, fulvestrant, letrozole, tamoxifen. Conditions recorded: Metastatic Breast Cancer.
Linked to the drug Mecapegfilgrastim because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Mecapegfilgrastim and the tag pipeline.
Shares Dalpiciclib and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.